

Amendments to the claims:

CLAIMS

1. (original) A process for purification of optically impure Ramipril to obtain Ramipril(I) having optical purity of at least 99.9 %, which comprises crystallizing optically impure Ramipril from an organic solvent selected from nitromethane, dimethoxymethane, diethoxymethane, and 2,2, -dimethoxy propane and mixtures thereof.
2. (original) The process as claimed in claim 1 wherein the organic solvent is diethoxymethane.
3. (original) A monohydrate of Ramipril(I), characterized by the following X-ray powder diffraction pattern

Diffraction angle	Relative Intensity (%)
2.8	
8.7	16
9.2	3
9.4	3
9.7	3
11.2	81
11.6	33
12.2	66
14.54	96
15.7	70
18.0	51
19.7	81
24.5	49
24.8	30

4. (original) The Ramipril(I) monohydrate as claimed in claim 3 having an X-ray diffractogram, or substantially the same X-ray diffractogram, as set out in Figure 1a.
5. (original) The Ramipril(I) monohydrate as claimed in claim 3 having DSC thermogram as described in Fig. 1c.
6. (original) The Ramipril(I) monohydrate as claimed in claim 3 having TGA thermogram as described in Fig. 1d.

7. (original) A process for preparation of Ramipril(I) monohydrate comprising of crystallizing optically impure Ramipril from a mixture of water and water-immiscible solvents.
8. (original) The process claimed in claim 7 wherein the ratio of water-immiscible solvent to water is in the range from 2 to 98% w/w.
9. (original) The process as claimed in claim 8 wherein the said water-immiscible solvent is selected from an aliphatic ester, an acetal, a hydrocarbon or a mixture thereof.
10. (original) The process as claimed in claim 8 wherein the said water-immiscible solvent is selected from diisopropyl ether, diethoxymethane, 2,2-dimethoxy propane, cyclohexane, methyl isobutyl ketone and ethyl acetate or a mixture thereof.
11. (original) A process for preparation of Ramipril(I) monohydrate comprising of crystallizing optically pure Ramipril(I) from water.
12. (currently amended) A pharmaceutical composition comprising an effective ACE inhibitory amount of Ramipril(I) monohydrate as claimed in any preceding claims claim 3, together with one or more pharmaceutically acceptable carriers, diluents or excipients thereof.